Eye Conditions Associated with GLP-1 Treatment When blood sugar drops significantly over weeks or months, some patients with pre-existing diabetic retinopathy experience temporary worsening of their condition

Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR

Abbreviations Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) have undergone evaluation across an extensive cardiovascular outcomes trial (CVOT) program
Wound Healing Research GHK-Cu has been investigated in wound healing models since the 1980s
Injectable semaglutide tends to win in a few specific situations